Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic investigation of response to duloxetine treatment in generalized anxiety disorder.

The pharmacogenomics journal - 1 Jun 2013

Perlis R H, Fijal B, Dharia S, Houston J P

Abstract excerpt

We examined genetic associations with duloxetine response in generalized anxiety disorder (GAD). Three pooled studies in patients with GAD receiving duloxetine 60-120 mg per day (N=164) or placebo (N=95) were used. Associations between 825 single-nucleotide polymorphisms (SNPs) in 61 candidate genes with change in Hamilton Anxiety Scale scores were examined with set-based testing (adjusted for the number of SNPs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anxiety Disorders
Share to Biomarkers, Pharmacological
Share to CRF Receptor, Type 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Depressive Disorder, Major

Share to Pharmacogenetics

Share to Psychiatric Status Rating Scales

Share to Receptors, Corticotropin-Releasing Hormone

Share to Thiophenes

Source

Identifiers

PMID: 22249355
DOI: 10.1038/tpj.2011.62

Genes

CRHR1
DRD3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic investigation of response to duloxetine treatment in generalized anxiety disorder.PMID 22249355Read ↗

Evaluation of genetic models for response in a randomized clinical trial of duloxetine in major depressive disorder.Semantic proximity Read ↗

Genome-wide association study of treatment response to venlafaxine XR in generalized anxiety disorder.Semantic proximity Read ↗

Genome-wide association studies of placebo and duloxetine response in major depressive disorder.Semantic proximity Read ↗

Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder.Semantic proximity Read ↗

Lack of influence of DAT1 and DRD2 gene variants on antidepressant response in generalized anxiety disorder.Semantic proximity Read ↗

GWAS-based machine learning approach to predict duloxetine response in major depressive disorder.Semantic proximity Read ↗

Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder.Semantic proximity Read ↗

Association of NPSR1 rs324981 polymorphism and treatment response to antidepressants in Chinese Han population with generalized anxiety disorder.Semantic proximity Read ↗

Baseline serum oxytocin and OXTR rs53576 genotype are not predictive of escitalopram response in generalized anxiety disorder.Semantic proximity Read ↗

Interaction between polymorphisms in serotonin transporter (SLC6A4) and serotonin receptor 2A (HTR2A) genes predict treatment response to venlafaxine XR in generalized anxiety disorder.Semantic proximity Read ↗

Whole-genome association analysis of treatment response in obsessive-compulsive disorder.Semantic proximity Read ↗

Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.